<DOC>
	<DOCNO>NCT00330044</DOCNO>
	<brief_summary>To determine safety Alimta use chemoradiation inoperable non small cell lung cancer</brief_summary>
	<brief_title>Alimta , Carboplatin Radiation Therapy Non Small Cell Lung Cancer</brief_title>
	<detailed_description>To determine maximal tolerate dose ( MTD ) toxicity Pemetrexed ( Alimta ) administer concurrently carboplatin thoracic radiation therapy . To determine , qualitatively , occurrence local tumor response identify regimen .</detailed_description>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<criteria>Unresectable Stage II , IIIB IV non small cell lung cancer . Evaluable disease planning CT scan Zubrod 01 Weight loss equal le 10 % 3 month prior diagnosis FEV1 great 1000cc Adequate hematologic , renal hepatic function Small cell cancer Stage I non small cell cancer Prior chemotherapy thoracic lower neck radiatio therapy</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>December 2016</verification_date>
</DOC>